ADAR1 Capital Management »

Beigene shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Beigene (BGNE) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Beigene

Tip: Access up to 7 years of quarterly data

All positions including Beigene held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Beigene by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $4.9M 32k 156.39
2023-12-31 $366k 2.0k 180.36

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Beigene

Baker Bros. Advisors
Capital Research and Management Company - Division 3
Hillhouse Capital Advisors
PRIMECAP Management Company
Baillie Gifford & Co
T. Rowe Price Associates
BlackRock
BlackRock
Point72 Asset Management
Capital International
Siren
Boxer Capital
First Trust Advisors
Connor, Clark & Lunn Investment Management
Bank of America Corporation

View all funds holding Beigene